• Prospects for the medicinal treatment of relapsed ovarian cancer 
To content

Prospects for the medicinal treatment of relapsed ovarian cancer 

HEALTH OF WOMAN. 2016.4(110):153–155 

Prospects for the medicinal treatment of relapsed ovarian cancer 

Ponomariova O., Bojko V., Kharchenko K.

Institute of experimental pathology, Oncology and radiobiology named after R. E. Kavetsky, NAS of Ukraine, Kyiv

National medical University named after O. O. Bogomolets, Kyiv

SІ «Institute of General and urgent surgery of a name of V. T. Zaitsev NAMS of Ukraine», Kharkov

Kyiv city clinical Oncology center, Kyiv 

The article examines recent clinical study conducted with new chemotherapeutic agents for the treatment of patients with ovarian cancer. Describes the new scheme and modification of existing standard patterns, and modes of administering drugs sequentially, evaluated data related to the use of new cytostatic drugs, and combinations thereof.

Key words: treatment of recurrent ovarian cancer, chemotherapy for recurrent ovarian cancer.


1. Hohlova SV. 2008. Novyie tendentsii v lechenii rasprostranennogo raka yaichnikov. Opuholi zhenskoy reproduktivnoy sistemyi 4:84–93.

2. Asadollahi R, Hyde CA, Zhong XY. 2010. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol. 118(1):81–7. http://dx.doi.org/10.1016/j.ygyno.2010.03.015; PMid:20421130

3. Audeh MW, Carmichael J, Penson RT. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 376(9737):245–51. http://dx.doi.org/10.1016/s0140-6736(10)60893-8

4. Crijns A, Boezen H. 2011. Prognostic factors in ovarian cancer: current evidence and future prospects. Eur J Cancer. 1:127–45. http://dx.doi.org/10.1016/S1359-6349(03)90017-6

5. Gelman K. 2010. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple negative breast cancer. J Clin Oncol. 28:15–17.

6. Joyce F Liu, William T Barry, Michael Birrer. 2014. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncology. 11:1207–1214. http://dx.doi.org/10.1016/S1470-2045(14)70391-2

7. Karlan BY, Oza AM, Hansen VL. 2010. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma. J Clin Oncol. 28:15–17.

8. Ledermann J et al. 2013, Sep 30. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. The European Cancer Congress. Abstract 10.

9. Matei D, Shen C, Fang F. 2011. A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC). J Clin Oncol. 29:201–23.

10. Matulonis UA, Berlin S, Ivy P. 2009. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 27(33):5601–6. http://dx.doi.org/10.1200/JCO.2009.23.2777; PMid:19826113 PMCid:PMC2792954

11. Monk BJ, Poveda A, Vergote I. 2014. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15:799–808. http://dx.doi.org/10.1016/S1470-2045(14)70244-X

12. Naumann RW, Coleman RL, Burger RA. 2011. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol. 29:201–18.

13. Kaye S et al. 2010. Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. Ann Oncol. 21:537–48.

14. Steffensen K, Waldstrom M et al. 2012. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Proc ASCO. abstr 5568.

15. Ali M et al. 2009. Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo. Clin. Cancer Res. 15(19):6106–6112. http://dx.doi.org/10.1158/1078-0432.ccr-09-0398

16. Weil MK, Chen AP. 2011. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 35(1):7–50. http://dx.doi.org/10.1016/j.currproblcancer.2010.12.002; PMid:21300207 PMCid:PMC3063418